KNSA Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 99% planned / 1% discretionary
Largest single sale: $12.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 4,600 | $80.30 | $369.4K | 29,062 −13.7% of holding | |
| Cole G Bradley | Director | Sell | 3,673 | $81.43 | $299.1K | 11,672 −23.9% of holding | |
| Paolini John F. 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 58,424 | $53.71 | $3.1M | 86,720 −40.3% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 48,565 | $54.02 | $2.6M | None left | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 2,141 | $54.01 | $115.6K | None left | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 22,544 | $54.01 | $1.2M | None left | |
| Patel Sanj K 4 fills | CHAIRMAN & CEO | Sell 10b5-1 | 483,654 | $51.86 | $25.1M | 409,019 −54.2% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 13,099 | $50.10 | $656.3K | 12,546 −51.1% of holding | |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 6,625 | $46.69 | $309.3K | 27,418 −19.5% of holding | |
| Moat Ross | CHIEF OPERATING OFFICER | Sell 10b5-1 | 1,703 | $46.69 | $79.5K | 12,029 −12.4% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 7,278 | $50.01 | $364.0K | None left | |
| Quart Barry D | Director | Sell 10b5-1 | 6,901 | $50.00 | $345.1K | 12,546 −35.5% of holding | |
| Moat Ross | CHIEF OPERATING OFFICER | Sell 10b5-1 | 2,367 | $48.58 | $115.0K | 12,029 −16.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.